Introduction and rationale
Prolonged sitting is associated with adverse health effects including an increased risk of cardiovascular disease (CVD), all-cause mortality, and diabetes [1, 2] . Stroke survivors are a high-risk population that spend 75% of their waking hours sitting and 52% in prolonged bouts of sitting (≥30 min) [3] , thus placing them at greater risk of further cardiovascular events. Hypertension is the leading modifiable risk https://doi.org/10.1016/j.conctc.2018.100310 Received 19 June 2018; Received in revised form 13 November 2018; Accepted 28 November 2018 factor associated with first stroke and recurrent stroke [4, 5] . Interrupting prolonged sitting with frequent bouts of physical activity (e.g. standing activities or walking) in non-stroke populations significantly reduces blood pressure (BP) [6] , postprandial glucose and insulin concentrations [7, 8] . In stroke survivors, our previous trial found that breaking up prolonged sitting with frequent, short breaks of light-intensity exercises while standing (STAND-EX) significantly reduced systolic blood pressure (SBP) by an average of 3.5 mmHg [9] . This improvement in SBP following frequent bouts of STAND-EX might present a promising target to reduce recurrent stroke risk amongst stroke survivors. While demonstrating proof of concept, the schedule of activity breaks (3 min every 30 min) is not clinically applicable in every-day life. Therefore, this new study builds on our previous BUSTStroke trial [9, 10] and aims to investigate the dose-response of STAND-EX bouts to reduce recurrent stroke risk and improve cardiometabolic health in stroke survivors.
The aims of this study are to determine the most effective dose of activity breaks that (i) produce clinically meaningful improvements in mean SBP (primary outcome), postprandial glucose, and insulin responses (secondary outcomes), and (ii) is safe and feasible.
Methods

Design
Community dwelling stroke survivors will be recruited to this laboratory based, dose-escalation study. Each participant will complete a familiarisation session followed by an uninterrupted sitting condition and two dose-escalation conditions (Fig. 1) 
Patient population
Stroke survivors with a moderate walking disability will be recruited to each cohort (n = 10/cohort).
Inclusion criteria: Stroke survivors > 3 months post-stroke; Functional Ambulation Classification (FAC) ≥ 3 (able to ambulate on level surfaces with or without supervision); walking speed ≥ 0.4 m/s; able to stand from sitting with minimal assistance (≤1 person); sit ≥ 7 h during waking hours; aged ≥ 18 years.
Exclusion criteria: Regularly engage in physical activity (≥150 min/ week); Body Mass Index (BMI) > 45 kg/m 2 ; smoker; pregnant; clinically diagnosed with an illness or condition that limits their ability to complete each condition; urinary frequency or urgency; diabetes or taking diabetic medication other than metformin.
Recruitment strategies
Participants will be recruited from the Hunter Stroke Research Volunteer Register, through advertisement, social media posts and presentations. Each participant will enrol in only one cohort.
Intervention
Familiarisation session
Baseline characteristics, including stroke profile (National Institutes of Health Stroke Scale [11] , Oxfordshire classification [12] and the Fatigue Assessment Scale [13] ), walking ability (10 m walk test, FAC), Australian diabetes risk (AUSDRISK assessment tool [14] ) and BP will be measured. Dietary intake will be recalled (24-h recall) under guidance of a dietitian. Participants will be fitted with a thigh-worn activity monitor (activPAL3; PAL Technologies Ltd) and ambulatory blood pressure monitor (ABPM 7100; Welch Allyn, Inc.) and instructed in the pre-experimental day dietary and activity restrictions.
Pre-experimental day protocol
To reduce dietary-induced variations in glucose and insulin, dietary intake will be standardised 24 h prior to, and during, each experimental condition based on the procedures employed in our previous trial [9, 10] . Participants will follow a dietitian prescribed meal plan and be provided with a standardised pre-experimental day evening meal and asked to abstain from alcohol, caffeine and moderate-to-vigorous physical activity for 48 h before the experimental conditions.
Physical activity and ambulatory blood pressure monitoring
Physical activity and sedentary time will be recorded using an activPAL3 for a minimum of 3 days prior to, and following, each experimental day. Ambulatory blood pressure (ABP) monitoring will continue for 24 h after each experimental day, with hourly ABP recordings. Participants will be asked to remain still whilst ABP measurements are taken. All monitors will be positioned on the participant's non-paretic limb.
Experimental day protocol
The protocol is adapted from a previous study completed in stroke survivors (BUST-Stroke) [15] . Participants will arrive at 07:30 on each experimental day and have their health status (presence of cold/flu-like symptoms) and adherence to pre-experimental day protocols determined. An intra-venous cannula will be inserted and fasting blood samples will be collected (08:00am and 08:30am). Blood samples will then be collected every 30 min during each 2 h postprandial period. BP (measured with ABPM) will also be measured every 30 min, with researchers and participants blinded to recordings. BP and blood samples will be taken before bouts of STAND-EX. A standardised breakfast and lunch meal will be provided at approximately 08:30am and 12:30pm, respectively. Participants will be required to consume standardised meals within 30 min. Heart rate, perceived exertion (using the BORG 0-10 scale) and time on task will be measured before and immediately after each bout of STAND-EX, which will vary according to dose escalation ( Table 1 ). Fatigue will be assessed periodically throughout the experimental day using a visual analogue scale. Water will be consumed ad libitum during the baseline condition, with total intake recorded and kept consistent between experimental conditions. Toilet breaks will be noted and timed. Table 2 summarises the testing day procedures.
The three experimental conditions will consist of:
1. Uninterrupted sitting -8 h of prolonged, uninterrupted sitting in a comfortable lounge chair (excluding toilet breaks).
Dose escalation 1 -Complete the prescribed dose of STAND-EX (calf-
raises, mini-squats and marching on the spot; BORG ≤ 3). 3. Dose escalation 2 -Complete an additional 10 min of STAND-EX above Dose escalation 1.
Each 5-min bout of STAND-EX will be completed in the following order and repeated 5 times: 20 s calf-raises, 20 s small amplitude squats, and 20 s marching on the spot. Table 1 describes the schedule of STAND-EX for each dose.
Dose-escalation
Escalation of STAND-EX will be completed in 10 min increments (2 x 5-min activity breaks). If a dose-limiting threshold (DLT) is not met, the next cohort will commence dose escalation at the final dose completed by the previous cohort. Once DLT is met, a final cohort will repeat the dose escalation of the penultimate cohort to confirm this is the maximum tolerable dose. Table 3 summarises dose escalation procedures.
Dose-limiting threshold
The DLT is failure to achieve at least 80% of the target time in STAND-EX due to fatigue, pain or effort. The maximum dose for a cohort will be considered reached if 70% or more of the cohort have met the DLT.
Blood sampling and analysis
Blood samples will be collected in a 4 mL EDTA tube at each sampling time-point (Table 2) to measure plasma glucose and insulin Table 1 Break protocol for light-intensity exercises while standing.
Table 2
Testing day procedure.
concentrations. Samples will be immediately refrigerated, centrifuged within 60 min of collection, aliquoted and stored in a −80°C freezer for later analysis. Enzyme-linked immunosorbent assay (ELISA) will be used to measure plasma insulin concentrations. Plasma glucose concentrations will be measured using the point of care i-STAT handheld blood analysis device (i-STAT, Abbot Point of Care Inc.).
Study outcomes
The primary outcome is mean SBP (within-participant, between condition differences) during and 24-h post experimental days. Secondary outcomes are within-participant, between-condition differences for plasma glucose and insulin. Safety will be measured by the number of adverse events, e.g. pain and discomfort from activity breaks. Feasibility assessments will include measures of protocol adherence and completion of activity breaks.
Sample size estimates
At study end, we will have data from n = 30 participants at the maximum tolerable dose of STAND-EX. With an assumed SD of 15 mmHg (based on previous exercise trials in stroke survivors) and a within-person correlation of 0.9, we will have 80% power to detect a within-person, between condition difference of 3.5 mmHg in SBP (α = 0.05).
Statistical analysis
SBP, blood glucose and insulin concentrations will be assessed using generalised linear mixed models with random intercepts to account for repeated measures on participants. On achieving the DLT, mean SBP, blood glucose and insulin will be compared with baseline to identify between condition differences. Safety and feasibility outcomes will be evaluated descriptively, and by comparing odds of adverse events across experimental conditions.
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Discussion
As an extension to previous research [15] , this trial will aim to ascertain the dose of light-intensity exercises most effective to improve mean SBP of stroke survivors that might reduce the risk of recurrent stroke. Results from this trial will inform future studies aiming to reduce the recurrent risk of stroke in stroke survivors.
Conclusion
This dose escalation trial will further develop our understanding of frequently interrupting prolonged sitting as a strategy to reduce blood pressure and recurrent stroke risk.
Conflicts of interest disclosures
Nil. Table 3 Dose-escalation protocol, representing a most effective dose of 40 min.
